Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:FBIO NASDAQ:PHAR NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.99-4.9%$7.19$3.54▼$8.25$171.22M0.8109,943 shs124,725 shsFBIOFortress Biotech$1.81-2.2%$1.89$1.33▼$2.36$54.70M1.76208,765 shs118,993 shsPHARPharming Group$10.96-1.4%$10.70$6.73▼$12.61$761.20M0.024,439 shs23,035 shsTLRYTilray Brands$0.57-2.1%$0.51$0.35▼$1.98$584.67M1.8547.21 million shs20.44 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical-4.90%-7.91%-0.71%-0.57%+25.95%FBIOFortress Biotech-2.16%-8.12%-1.09%-1.09%-13.40%PHARPharming Group-1.35%+6.82%+2.91%+21.52%+28.19%TLRYTilray Brands-2.10%-17.40%+17.21%+24.96%-71.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDERMJourney Medical2.2115 of 5 stars3.51.00.00.02.81.70.6FBIOFortress Biotech2.4755 of 5 stars3.51.00.00.02.13.30.6PHARPharming Group3.0169 of 5 stars3.55.00.00.03.40.00.6TLRYTilray Brands2.8903 of 5 stars3.13.00.00.03.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 3.00Buy$9.5035.91% UpsideFBIOFortress Biotech 3.00Buy$21.001,060.22% UpsidePHARPharming Group 3.00Buy$30.00173.72% UpsideTLRYTilray Brands 2.20Hold$1.92237.03% UpsideCurrent Analyst Ratings BreakdownLatest DERM, FBIO, PHAR, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025TLRYTilray BrandsZelman & AssociatesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$56.13M2.90N/AN/A$0.91 per share7.68FBIOFortress Biotech$57.67M0.93N/AN/A($0.06) per share-30.17PHARPharming Group$297.20M2.53$0.07 per share149.88$3.25 per share3.37TLRYTilray Brands$821.31M0.70$0.15 per share3.81$1.48 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)FBIOFortress Biotech-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)PHARPharming Group-$11.84M-$0.13N/A365.33N/A-2.19%-3.38%-1.82%N/ATLRYTilray Brands-$244.98M-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)Latest DERM, FBIO, PHAR, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025FBIOFortress Biotech-$0.31N/AN/AN/A$14.53 millionN/A8/11/2025Q2 2025DERMJourney Medical-$0.06N/AN/AN/A$14.93 millionN/A7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 million7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 million5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical1.071.341.03FBIOFortress Biotech1.741.721.55PHARPharming Group0.392.762.00TLRYTilray Brands0.202.461.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%FBIOFortress Biotech96.51%PHARPharming Group0.03%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%FBIOFortress Biotech27.90%PHARPharming Group2.07%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9023.30 million19.80 millionN/AFBIOFortress Biotech17029.57 million21.32 millionOptionablePHARPharming Group28068.51 million67.10 millionNot OptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableDERM, FBIO, PHAR, and TLRY HeadlinesRecent News About These CompaniesTilray Brands, Inc. (TLRY) Expands Beverage Portfolio with Molson Coors Acquisition5 hours ago | insidermonkey.comTilray Brands, Inc. (TLRY) Expands Beverage Portfolio with Molson Coors Acquisition5 hours ago | finance.yahoo.comAtb Cap Markets Estimates Tilray Brands Q1 EarningsAugust 2 at 3:41 AM | americanbankingnews.comTilray Brands (NASDAQ:TLRY) Stock Price Down 2.6% - Here's WhyAugust 1 at 2:00 PM | marketbeat.comShould You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?August 1 at 9:15 AM | zacks.comAtb Cap Markets Weighs in on Tilray Brands Q1 EarningsAugust 1 at 6:57 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Down 1% - Time to Sell?July 31 at 4:24 PM | marketbeat.comTilray Brands, Inc. Stock (TLRY) Opinions on Q4 Earnings ReportJuly 31 at 1:12 PM | quiverquant.comQTilray's Unique Strategy Could Make It A Winner As Cannabis, Beverages, And Wellness MatureJuly 31 at 11:33 AM | benzinga.comInsider Buying: Tilray Brands, Inc. (NASDAQ:TLRY) CFO Buys 33,500 Shares of StockJuly 31 at 7:01 AM | insidertrades.comAtb Cap Markets Forecasts Tilray Brands Q4 EarningsJuly 31 at 7:00 AM | marketbeat.comFY2026 EPS Estimates for Tilray Brands Increased by AnalystJuly 31 at 7:00 AM | marketbeat.comIs Tilray Brands a Dirt Cheap Growth Stock or Just a Bad Buy?July 31 at 6:53 AM | msn.comTilray Brands' (TLRY) "Neutral" Rating Reiterated at Zelman & AssociatesJuly 31 at 2:03 AM | americanbankingnews.comIrwin D. Simon Buys 165,000 Shares of Tilray Brands, Inc. (NASDAQ:TLRY) StockJuly 30 at 7:37 PM | marketbeat.comCarl A. Merton Acquires 33,500 Shares of Tilray Brands, Inc. (NASDAQ:TLRY) StockJuly 30 at 3:46 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Up 5.4% - Here's WhyJuly 30 at 3:26 PM | marketbeat.comCannabis Stocks Are at a Turning Point: Is Now the Time to Invest?July 30 at 10:35 AM | marijuanastocks.comMTilray Brands Reports In-Line Q4-2025 And FY2025 Results Amidst Weakening SectorJuly 29, 2025 | seekingalpha.comTilray Brands (NASDAQ:TLRY) Shares Down 11.8% - Should You Sell?July 29, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Down - Here's What HappenedJuly 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug Power3 High-Risk, High-Reward Stocks With Explosive UpsideBy Nathan Reiff | July 16, 2025View 3 High-Risk, High-Reward Stocks With Explosive UpsideTilray Shares Blazing: What's Behind the 55% Rally This Month?By Nathan Reiff | July 14, 2025View Tilray Shares Blazing: What's Behind the 55% Rally This Month?DERM, FBIO, PHAR, and TLRY Company DescriptionsJourney Medical NASDAQ:DERM$6.99 -0.36 (-4.90%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.00 +0.01 (+0.21%) As of 08/1/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Fortress Biotech NASDAQ:FBIO$1.81 -0.04 (-2.16%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.86 +0.05 (+2.76%) As of 08/1/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Pharming Group NASDAQ:PHAR$10.96 -0.15 (-1.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.99 +0.03 (+0.26%) As of 08/1/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Tilray Brands NASDAQ:TLRY$0.57 -0.01 (-2.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.57 +0.00 (+0.23%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
